Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection

Bibliography

• Muto CA, Pokrywka M, Shutt K, A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005;26:273-80
   PubMed Web of Science ®Google Scholar
• Loo VG, Poirier L, Miller MA, A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442-9
   PubMed Web of Science ®Google Scholar
• McDonald LC, Killgore GE, Thompson A, An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353:2433-41
   PubMed Web of Science ®Google Scholar
• Hubert B, Loo VG, Bourgault AM, A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Quebec. Clin Infect Dis 2007;44:238-44
   PubMed Web of Science ®Google Scholar
• Kuijper EJ, Coignard B, Tull P, Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006;12(Suppl 6):2-18
   PubMed Web of Science ®Google Scholar
• McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996 – 2003. Emerg Infect Dis 2006;12:409-15
   PubMed Web of Science ®Google Scholar
• Kuijper EJ, Barbut F, Brazier JS, Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. Euro Surveill 2008;1-7
   Google Scholar
• Labbé AC, Poirier L, MacCannell D, Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 Strain. Antimicrob Agents Chemother 2008;52:3180-7
   PubMed Web of Science ®Google Scholar
• Miller M, Gravel D, Mulvey M, and the Canadian Nosocomial Infection Surveillance Program (CNISP). Hospital-acquired Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis 2010;50:194-201
   PubMed Web of Science ®Google Scholar
• Debast SB, van Leengoed LA, Goorhuis A, Clostridium difficile PCR ribotype 078 toxinotype V found in diarrhoeal pigs identical to isolates from affected humans. Environ Microbiol 2009;11:505-11
   PubMed Web of Science ®Google Scholar
• Goorhuis A, Bakker D, Corver J, Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 2008;47:1162-70
   PubMed Web of Science ®Google Scholar
• Bauer MP, Notermans DW, van Benthem BHB, First results of the European Clostridium difficile infection survey (ECDIS) [abstract O86]. 19th European Congress of Clinical Microbiology and Infectious Diseases; 16 – 19 May 2009; Helsinki, Finland
   Google Scholar
• O'Neill GL, Beaman MH, Riley TV. Relapse versus reinfection with Clostridium difficile. Epidemiol Infect 1991;107:627-35
   PubMed Web of Science ®Google Scholar
• Johnson S, Adelmann A, Clabots CR, Recurrences of Clostridium difficile not caused by the original infecting organism. J Infect Dis 1989;159:340-3
   PubMed Web of Science ®Google Scholar
• Louie T, Gerson M, Grimard D, Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhea (CDAD) [abstract K-425a]. 47th Annual ICAAC; 17 September 2007; Chicago, IL, USA
   Google Scholar
• Golan Y, Mullane KM, Miller MA, Low recurrence rate among patients with C. difficile infection treated with fidaxomicin [abstract L1-1639]. 49th ICAAC; 12 – 15 September 2009; San Francisco, CA, USA
   Google Scholar
• Mullane KM, Miller MA, Weiss K, Effect of concomitant antibiotics on treatment of Clostridium difficile infection (CDI) with fidaxomicin or vancomycin [abstract LB-14]. 47th Annual Meeting of the Infectious Disease Society of America; 29 October – 1 November 2009; Philadelphia, PA, USA
   Google Scholar
• Miller M, Florencio S, Eastmond J, Reynolds S. Results of two prospective randomized studies of Lactobacillus GG (LGG) to prevent C. difficile infection (CDI) in hospitalized adults receiving antibiotics [abstract K-4200]. 48th Annual ICAAC/46th Annual IDSA Meeting; 25 – 28 October 2008; Washington DC, USA
   Google Scholar
• Miller M. The fascination with probiotics for Clostridium difficile infection: lack of evidence for prophylactic or therapeutic efficacy. Anaerobe 2009;15:281-4
   PubMed Web of Science ®Google Scholar
• Hickson M, D'souza AL, Muthu N, Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomized double blind placebo controlled trial. BMJ 2007;335:80-4
   PubMed Web of Science ®Google Scholar
• Wilcox M, Sandoe JA. Probiotics and diarrhea: data are not widely applicable. BMJ 2007;335:13
   Google Scholar
• Kotloff KL, Wasserman SS, Losonsky GA, Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun 2001;69:988-95
   PubMed Web of Science ®Google Scholar
• Aboudola S, Kotloff KL, Kyne L, Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun 2003;71:1608-10
   PubMed Web of Science ®Google Scholar
• Sougioultzis S, Kyne L, Drudy D, Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 2005;128:764-70
   PubMed Web of Science ®Google Scholar
• US National Institutes of Health. Study of a Clostridium Difficile Toxoid Vaccine (ACAM-CDIFF™) in Subjects With Clostridium Difficile Infection. Available from: http://clinicaltrials.gov/cta/show/NCT00772343 [Last accessed 23 February 2010]
   Google Scholar
• Lowy I, Molrine DC, Leav BA, Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010;362:197-205
   PubMed Web of Science ®Google Scholar
• Byker GL, Dinh MT, Gunaratnam NT, Management of Clostridium difficile infection: survey of practices and compliance with national guidelines among primary care physicians. Infect Control Hosp Epidemiol 2009;30:397-9
   PubMed Web of Science ®Google Scholar
• Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302-7
   PubMed Web of Science ®Google Scholar
• Pepin J, Valiquette L, Alary ME, Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. Can Med Assoc J 2004;171:466-72
   PubMed Web of Science ®Google Scholar
• Kuijper EJ, Wilcox MH. Decreased effectiveness of metronidazole for the treatment of Clostridium difficile infection? Clin Infect Dis 2008;47:63-5
   PubMed Web of Science ®Google Scholar
• Baines SD, O'Connor R, Freeman J, Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 2008;62:1046-52
   PubMed Web of Science ®Google Scholar
• Miller M, Bernard L, Thompson M, Lack of increased colonization with vancomycin-resistant enterococci during preferential use of vancomycin for treatment during an outbreak of healthcare-associated Clostridium difficile infection. Infect Control Hosp Epidemiol (In press)
   Google Scholar
• Bauer MP, Kuijper EJ, Van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CD). Clin Microbiol Infect 2009;15:1067-79
   PubMed Web of Science ®Google Scholar
• Cohen SH, Gerding DN, Johnson S, Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010;431-55
   Google Scholar
• Teasley DG, Gerding DN, Olson MM, Prospective randomized trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet 1983;2:1043-6
   PubMed Web of Science ®Google Scholar
• Gerber M, Ackermann G. OPT-80, a macrocyclic antimicrobial agent for the treatment of Clostridium difficile infections: a review. Expert Opin Investig Drugs 2008;17:547-53
   PubMed Web of Science ®Google Scholar
• Johnson AP. Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic. Curr Opin Investig Drugs 2007;8:168-73
   PubMed Web of Science ®Google Scholar
• Shue Y-K, Du C-JF, Chiou M-H, Tiacumicin production. WO2004014295; 2004
   Google Scholar
• Cavalleri B, Arnone A, Di Modugno E, Structure and biological activity of lipiarmycin b. J Antibiotics 1988;41:308-15
   PubMed Web of Science ®Google Scholar
• Theriault RJ, Karwowski JP, Jackson M, Tiacumicins, a novel complex of 18-membered macrolide antibiotics. I. Taxonomy, fermentation and antibacterial activity. J Antibiotics 1987;40:567-74
   PubMed Web of Science ®Google Scholar
• Hochlowski JE, Swanson SJ, Ranfranz LM, Tiacumicins, a novel complex of 18-membered macrolide antibiotics. II. Isolation and structure determination. J Antibiotics 1987;40:575-88
   PubMed Web of Science ®Google Scholar
• Gualtieri M, Villain-Guillot P, Latouche J, Mutation in the Bacillus subtilis RNA polymerase beta subunit confers resistance to lipiarmycin. Antimicrob Agents Chemother 2006;50:401-2
   PubMed Web of Science ®Google Scholar
• Wösten MMSM. Eubacterial sigma-factors. FEMS Microbiol Rev 1998;22:127-50
   PubMed Web of Science ®Google Scholar
• Finegold SM, Molitoris D, Vaisanen ML, In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrob Agents Chemother 2004;48:4898-902
   PubMed Web of Science ®Google Scholar
• Credito KL, Appelbaum PC. Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species. Antimicrob Agents Chemother 2004;48:4430-4
   PubMed Web of Science ®Google Scholar
• Ackermann G, Loffler B, Adler D, Rodloff AC. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother 2004;48:2280-2
   PubMed Web of Science ®Google Scholar
• Swanson RN, Hardy DJ, Shipkowitz NL, In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile. Antimicrob Agents Chemother 1991;35:1108-11
   PubMed Web of Science ®Google Scholar
• Hecht DW, Galang MA, Sambol SP, In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007;51:2716-19
   PubMed Web of Science ®Google Scholar
• Babakhani F, Robert N, Shangle S, Antimicrobial activity and post-antibiotic effect (PAE) of OPT-80, a new macrocyclic compound, against Clostridium difficile [abstract E-2048]. 44th ICAAC; 30 October – 2 November 2004; Washington DC, USA
   Google Scholar
• Karlowsky JA, Laing NM, Zhanel GG. In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile. Antimicrob Agents Chemother 2008;52:4163-5
   PubMed Web of Science ®Google Scholar
• Miller M, Mastrantonio P, Blanchette R, Rifampin, rifaximin, OPT-80 and tigecycline susceptibility of C. difficile strains from Canada and Italy: rifamycin resistance entirely predicted by rifampin E-test with divergent rifamycin resistance among the two countries [abstract C2-1958]. 49th ICAAC; 12 – 15 September 2009; San Franciso, CA, USA
   Google Scholar
• Babakhani FK, Seddon J, Robert N, Narrow spectrum activity and low fecal binding of OPT-80 and its major hydrolysis metabolite (OP-1118) [abstract E-2076]. 47th ICAAC; 17 – 20 September 2007; Chicago, USA
   Google Scholar
• Babakhani F, Seddon J, Robert N, Effect of inoculum, pH, and cations on the in vitro activity of OPT-80 vs Clostridium difficile [abstract D-1648]. 45th ICAAC; 16 – 19 December 2005; Washington DC, USA
   Google Scholar
• Babakhani F, Shangle S, Robert N, Resistance development, cross-resistance, and synergy studies of OPT-80 [abstract E-2047]. 44th ICAAC, Washington DC, USA
   Google Scholar
• Okumu F, Walsh RB, Sears P, Shue Y-K. Safety and pharmacokinetics of OPT-80, a novel antibiotic for treatment of Clostridium difficile associated diarrhea (CDAD) [abstract F-726]. 44th ICAAC; 30 October – 2 November 2004; Washington DC, USA
   Google Scholar
• Louie T, Miller M, Donskey C, Safety, pharmacokinetics and outcomes of PAR-101 in healthy subjects and patients with Clostridium difficile-associated diarrhea (CDAD) [abstract LB2-29]. 45th ICAAC; 16 – 19 December 2005; Washington DC, USA
   Google Scholar
• Sears P, Louie TJ, Mullane KM, Pharmacokinetics/pharmacodynamics (PK/PD) of fidaxomicin in treatment of Clostridium difficile infection (CDI) [abstract A1-1949]. 49th ICAAC; 12 – 15 September 2009; San Francisco, CA, USA
   Google Scholar
• Shue YK, Sears PS, Shangle S, Safety, tolerance and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses. Antimicrob Agents Chemother 2008;52:1391-5
   PubMed Web of Science ®Google Scholar
• Louie T, Miller M, Donskey C, Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob Agents Chemother 2009;53:223-8
   PubMed Web of Science ®Google Scholar
• Sears P, Babakhani F, Citron DM, Typing and susceptibility of bacterial isolates from the OPT-80 (PAR-101) phase 2A study for C. difficile-associated diarrhea. 9th Biennial Congress of the Anaerobe Society of the Americas; 24 – 27 June 2008; Long Beach, CA, USA
   Google Scholar
• Louie TJ, Emery J, Krulicki W, OPT-80 eliminates Clostridium difficile and is sparing of Bacteroides species during treatment of C. difficile infection. Antimicrob Agents Chemother 2009;53:261-3
   PubMed Web of Science ®Google Scholar
• Globe NewsWire. Optimer Pharmaceuticals Advances Difimicin Into Phase 3 Clinical Trial. Available from: http://www.globenewswire.com/newsroom/news.html?d=115459 [Last accessed 9 February 2010]
   Google Scholar
• Gerding DN, Sambol SP, Nagaro K, Restriction endonuclease analysis (REA) typing of Clostridium difficile in a phase 3 treatment trial of fidaxomicin vs vancomycin: decreased cure rate for epidemic BI/NAP1/027 strain [abstract L1-1642]. 49th ICAAC; 12 – 15 September 2009; San Francisco, CA, USA
   Google Scholar
• Louie TJ, Mullane KM, Weiss K, A randomized, double-blind clinical trial of OPT-80 versus vancomycin in Clostridium difficile infection [abstract O148]. 19th European Congress of Clinical Microbiology and Infectious Diseases; 16 – 19 May 2009; Helsinki, Finland
   Google Scholar
• Gorbach S, Weiss K, Sears P, Pullman J. Safety of fidaxomicin versus vancomycin in treatment of Clostridium difficile infection [abstract L1-1640]. 49th ICAAC; 12 – 15 September 2009; San Francisco, CA, USA
   Google Scholar
• Nerandzic MM, Mullane K, Miller M, Acquisition and overgrowth of vancomycin-resistant enterococci in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection [abstract K-1915]. 49th ICAAC; 12 – 15 September 2009; San Francisco, CA, USA
   Google Scholar
• Miller MA, Mullane KM, Weiss K, Faster time to resolution of diarrhea with fidaxomicin vs. vancomycin in patients with Clostridium difficile infection (CDI) [abstract 422]. 47th Annual Meeting of the Infectious Disease Society of America; 29 October – 1 November 2009; Philadelphia PA, USA
   Google Scholar
• Optimer Pharmaceuticals completes enrollment in second fidaxomicin phase 3 clinical trial in patients with Clostridium difficile infection. Available from: http://optimerpharma.com/ news.asp?news_story= 102&page_num=&year=2009 [Last accessed 4 May 2010]
   Google Scholar
• Crook D, Weiss K, Cornely OA, Randomized clinical trial in Clostridium difficile infection confirms equivalent cure rate and lower recurrence rate of fidaxomicin versus vancomycin [abstract LB2401]. 20th European Congress of Clinical Microbiology and Infectious Diseases; 10 – 13 April 2010; Vienna, Austria
   Google Scholar
• Berenbaum PL. Oral rifaximin in treatment of Clostridium difficile-associated diarrhea [abstract]. Am J Gastro 2006;101:S199-200
   PubMed Web of Science ®Google Scholar
• Pullman J, Prieto J, Leach TS. Ramoplanin vs vancomycin in the treatment of Clostridium difficile diarrhea: a phase 2 study [abstract K-985a]. 44th ICAAC; 30 October – 2 November 2004; Washington DC, USA
   Google Scholar
• Musher DM, Logan N, Hamill RJ, Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 2006;43:421-7
   PubMed Web of Science ®Google Scholar
• Musher DM, Logan N, Bressler AM, Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis 2009;48:e41-6
   PubMed Web of Science ®Google Scholar